Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.26 USD | -4.55% | -8.03% | +1.61% |
Apr. 23 | Averoa Seeks EU Approval for Chronic Kidney Disease Drug | MT |
Apr. 16 | Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement | CI |
Financials (USD)
Sales 2024 * | 189M | Sales 2025 * | 164M | Capitalization | 264M |
---|---|---|---|---|---|
Net income 2024 * | -63M | Net income 2025 * | -70M | EV / Sales 2024 * | 1.4 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.6 x |
P/E ratio 2024 * |
-4.3
x | P/E ratio 2025 * |
-3.98
x | Employees | 167 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.33% |
Latest transcript on Akebia Therapeutics, Inc.
1 day | -4.55% | ||
1 week | -8.03% | ||
1 month | -31.15% | ||
3 months | -25.00% | ||
6 months | +43.18% | ||
Current year | +1.61% |
Managers | Title | Age | Since |
---|---|---|---|
John Butler
CEO | Chief Executive Officer | 59 | 13-06-30 |
Tracey Vetterick
ADM | Chief Administrative Officer | - | 22-03-31 |
Michel Dahan
COO | Chief Operating Officer | 45 | 12-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Rogers
BRD | Director/Board Member | 64 | 18-12-11 |
Adrian Adams
CHM | Chairman | 73 | 18-12-11 |
Director/Board Member | 65 | 21-02-15 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 1.26 | -4.55% | 4,653,593 |
24-04-29 | 1.32 | -1.49% | 1,974,332 |
24-04-26 | 1.34 | +0.75% | 2,475,964 |
24-04-25 | 1.33 | -2.92% | 2,561,124 |
24-04-24 | 1.37 | -.--% | 1,535,781 |
Delayed Quote Nasdaq, April 30, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.61% | 264M | |
-3.46% | 102B | |
+1.41% | 96.09B | |
+2.13% | 22.28B | |
-15.84% | 21.4B | |
-10.12% | 18.14B | |
-39.98% | 17.02B | |
-14.65% | 16.09B | |
+4.39% | 13.83B | |
+31.35% | 11.97B |
- Stock Market
- Equities
- AKBA Stock